Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

@article{Verstovsek2011ResultsOC,
  title={Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).},
  author={Srdan Verstovsek and Ruben A. Mesa and Jason R. Gotlib and Richard S. Levy and Vicram Gupta and John F. DiPersio and John Catalano and Michael Deininger and Carol B Miller and Richard T. Silver and Moshe Talpaz and Elliott F. Winton and Jimmie H. Harvey and Kris Vaddi and Susan K Erickson-Viitanen and I Koumenis and Weijing Sun and Victor A Sandor and Hagop M Kantarjian},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={6500}
}
6500 Background: Dysregulated JAK-STAT signaling is a key feature in MF, which is characterized by splenomegaly, debilitating symptoms, cytopenias and shortened survival. There are currently no effective drug therapies for MF. 424 is a selective JAK 1 and 2 inhibitor with clinical activity in MF. METHODS Patients (pts) with intermediate-2 or high-risk MF were randomized to start PB or 424 at a dose of 15 mg or 20 mg PO BID depending on baseline platelet count (100-200 X 109/L or >200 X 109/L… CONTINUE READING
14 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…